Senators seek information from FDA and abortion drug manufacturers on mifepristone
U.S. senators who oppose abortion sent investigatory letters to three mifepristone manufacturers and the FDA. The letters seek information regarding the manufacturing, sales, and marketing of the abortion drug. The action stems from frustration among pro-life groups over the unclear status of the FDA's review of mifepristone. The letters were signed by Republican senators, including the chairman of the Senate HELP Committee and the chair of the Senate Pro-Life Caucus. Senator Cassidy stated that chemical abortion drug makers profit while potentially risking mothers' lives and facilitating online sales without regard for safety.
about 18 hours ago
A group of Republican senators, including Bill Cassidy (R-La.), Cindy Hyde-Smith (R-Miss.), Steve Daines (R-Mont.), James Lankford (R-Okla.), and Lindsey Graham (R-S.C.), sent letters on March 25, 2026, to three mifepristone manufacturers—Evita Solutions, GenBioPro, and Danco Laboratories—requesting details on manufacturing, sales, and marketing.1
They also wrote to the FDA, urging action against unapproved and misbranded versions sold online.1
Senators expressed concerns over serious adverse events, noting more than 1 in 10 women experience them with mifepristone.1
They criticized online sales for bypassing in-person dispensing, increasing risks of coercion, abuse, and health dangers.1
Cassidy stated manufacturers profit from "killing innocent children" while endangering mothers.1
The letters stem from frustration over unclear FDA review status of mifepristone, approved in 2000 for early abortions.1
Senators called for reinstating safeguards like in-person evaluations, citing FDA's own warnings against online purchases.1
Hyde-Smith urged immediate FDA action against life-threatening unapproved variants.1
Abortions rose to 1.13 million in 2025, the highest since 2009, driven by mail-order drugs post-Dobbs v. Jackson decision.1
Pro-life groups like Susan B. Anthony Pro-Life America note this reverses prior declines, fueled by Biden-era policies.1
A Pew poll showed 55% support for legal medication abortion, but 67% back in-person requirements per CRC Research.1
Pro-choice advocates, like Reproductive Freedom for All, view restrictions as a nationwide ban effort; mifepristone also aids miscarriage care.1
Investigate Catholic Church stance on regulating mifepristone
The Catholic Church teaches that direct abortion, including chemical methods that intentionally terminate a pregnancy by killing the unborn child, is always gravely immoral and constitutes a crime against human life. From the moment of conception, human life must be respected absolutely, as affirmed in Scripture (e.g., Jer 1:5; Ps 139:15) and Tradition, including the Didaché and Vatican II's Gaudium et Spes 51. Those who procure a completed abortion incur latae sententiae excommunication (Canon 1398), applicable to formal cooperators.
Mifepristone (RU-486), used in chemical abortions often via telemedicine, falls under this prohibition as it directly intends the termination of pregnancy before viability, which the Ethical and Religious Directives for Catholic Health Care Services (Directive 45) defines as abortion and deems "never permitted." Catholic health care institutions must avoid even material cooperation with abortion providers to prevent scandal.
Church teaching distinguishes direct abortion (never licit) from procedures treating a serious maternal pathology that may indirectly result in fetal death, provided the death is not intended and cannot be postponed. For example, Pius XII allowed surgeries with inevitable but unintended fetal loss if a high good like the mother's life is at stake. Mifepristone, however, targets the fetus directly and lacks this justification.
The United States Conference of Catholic Bishops (USCCB), in a 2025 joint letter to FDA Commissioner Martin A. Makary, explicitly addresses mifepristone regulation, urging improved safety protocols and health protections, particularly for telemedicine chemical abortions. Key concerns include:
The USCCB endorses the Catholic Medical Association's policy paper, calling on the FDA to act ethically to protect women, emphasizing mifepristone's dangers to health and dignity. This reflects broader magisterial opposition to facilitating abortion, as chemical abortifacients like the "morning-after pill" (similar mechanism) are absolutely unlawful to distribute, prescribe, or take.
While sources do not detail global regulatory proposals beyond the USCCB's FDA letter, the Church's consistent doctrine implies support for regulations restricting access to abortifacients, aligning with calls to combat "dealers of death" in related contexts (e.g., drugs undermining dignity). Scholarly sources highlight moral complicity in funding or mandating abortifacient coverage, reinforcing opposition to deregulation.
In summary, the Church condemns mifepristone-enabled abortions as gravely immoral and urges stricter regulation to mitigate harms, prioritizing life protection over access. For full fidelity, consult official Magisterium documents.